Pomalidomide in the treatment of relapsed multiple myeloma

Future Oncology

Volumn 9, Issue 7, 2013, Pages 939-948

  Forsberg, Peter A ^a   Mark, Tomer M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

IMiD; multiple myeloma; pomalidomide; refractory; relapsed

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE; PREDNISONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; THALIDOMIDE;

EID: 84880249695     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.105     Document Type: Article

References (77)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 335(2), 91-97 (1996).
2. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348(19), 1875-1883 (2003).
3. Singhal S, Mehta J, Desikan R et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
4. Rajkumar SV, Blood E, Vesole D, Fonseca R, Griepp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24(3), 431-436 (2006).
5. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
6. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13), 4050-4053 (2005).
7. Schey SA, Fields P, Bartlett JB et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22(16), 3269-3276 (2004).
8. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol. 141(1), 41-51 (2008).
9. Richardson P, Siegel D, Baz R et al. A Phase 1/2 multi-center, randomized, open-label, dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM) who have received prior treatment that includes lenalidomide and bortezomib. Presented at: 13th International Myeloma Workshop. Paris, France, 3-6 May 2011.
10. Richardson PG, Lonial S, Jakubowiak A et al. Impact of POM + LoDEX on disease parameters and cytogenetic status in relapsed and refractory multiple myeloma (RRMM). Presented at: 14th International Myeloma Workshop. Kyoto, Japan, 3-7 April 2013.
11. Vij R, Richardson PG, Jagannath S et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2012.
12. Jagannath S, Hofmeister C, Siegel D et al. Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT): Updated Phase 2 results and age subgroup analysis. Presented at: American Society of Hematology Annual Meeting. Atlanta, GA, USA, 8-11 December 2012.
13. Leleu X, Attal M, Arnulf B et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 121(11), 1968-1975 (2013).
14. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
15. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/Dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11), 1934-1939 (2010).
16. Lacy MQ, Allred JB, Gertz MA et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease. Blood 118(11), 2970-2975 (2011).
17. Leleu XL, Roussel MR, Arnulf BA et al. Enhanced activity of pomalidomide and dexamethasone in relapsed refractory myeloma irrespective to efficacy in their last prior line of therapy. Presented at: 17th Congress of the European Hematology Association. Amsterdam, The Netherlands, 14-17 June 2012.
18. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516-2520 (2008).
19. Attal M, Lauwers-Cances V, Marit G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1782-1791 (2012).
20. McCarthy PL, Owzar K, Hofmeister CC et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1770-1781 (2012).
21. Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366(19), 1759-1769 (2012).
22. Rossi A, Mark T, Jayabalan D et al. BiRD (clarithromycin, lenalidomide, dexamethasone): An update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121(11), 1982-1985 (2011).
23. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study. Leukemia 26(1), 149-157 (2012).
24. Egan JB, Shi CX, Tembe W et al. Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood 120(5), 1060-1066 (2012).
25. Schutt P, Brandhorst D, Stellberg W et al. Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk. Lymphoma 47(8), 1570-1582 (2006).
26. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563-579 (2007).
27. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin. Infect. Dis. 49(8), 1211-1225 (2009).
28. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28(33), 4976-4984 (2010).
29. Eleutherakis-Papaiakovou V, Bamias A, Gika D et al. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk. Lymphoma 48(2), 337-341 (2007).
30. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metab. Toxicol. 4(8), 1065-1074 (2008).
31. Stewart AK, Chang H, Trudel S et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia 21(11), 2358-2359 (2007).
32. Richardson PG, Xie W, Mitsiades C et al. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27(21), 3518-3525 (2009).
33. Tosi P, Zamagni E, Cellini C et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. 74(3), 212-216 (2005).
34. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24(1), 22-32 (2010).
35. Zhu YX, Korteum KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma 54(4), 683-687 (2013).
36. Rychak E, Mendy D, Miller K et al. Overcoming resistance: The use of pomalidomide (pom) and dexamethasone (dex) in re-sensitizing lenalidomide (len)-resistant multiple myeloma (MM) cells. Presented at: 13th International Myeloma Workshop. Paris, France, 3-6 May 2011.
37. Bartlett JB, Drege K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4), 314-322 (2004).
38. Knight R. IMiDs: A novel class of immunomodulators. Semin. Oncol. 32(4 Suppl. 5), 24-30 (2005).
39. Hoffmann M, Kasserra C, Reyes J et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother. Pharmacol. 71(2), 489-501 (2013).
40. Chen N, Wen L, Lau H, Surapaneni S, Kumar G. Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother. Pharmacol. 69(3), 789-797 (2012).
41. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 69(18), 7347-7356 (2009).
42. Li S, Pal R, Monaghan SA et al
43. Verhelle D, Corral LG, Wong K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 67(2), 746-755 (2007).
44. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 99(22), 4525-4530 (2002).
45. Harousseau JL, Dimopoulos MA, Wang M et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10), 1738-1744 (2010).
46. Gandhi AK, Kang J, Capone L et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr. Cancer Drug Targets 10(2), 155-167 (2010).
47. Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C. Enhanced cross-priming of naive CD8+ T cells by DCs treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology doi:10.1111/imm.12087 (2013) (Epub ahead of print).
48. Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58(7), 1033-1045 (2009).
49. Dredge K, Marriott JB, Todryk SM et al. Protective anti-tumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168(10), 4914-4919 (2002).
50. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163(1), 380-386 (1999).
51. Xu Y, Li J, Ferguson GD et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114(2), 338-345 (2009).
52. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1), 210-216 (2001).
53. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57(12), 1849-1859 (2008).
54. Pal R, Monaghan SA, Hassett AC et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 115(3), 605-614 (2010).
55. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 104(3), 607-618 (2004).
56. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 15(12), 1950-1961 (2001).
57. Dankbar B, Pado T, Leo R et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95(8), 2630-2636 (2000).
58. Bolzoni M, Storti P, Bonomini S et al. The immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules. Exp. Hematol. 41(4), 387-397 (2013).
59. Lu L, Payvandi F, Wu L et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res. 77(2), 78-86 (2009).
60. Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 87(10), 1166-1172 (2002).
61. Anderson G, Gries M, Kurihara N et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8), 3098-3105 (2006).
62. Ito T, Ando H, Suzuki T et al. Identification of a primary target of thalidomide teratogenicity. Science 327(5971), 1345-1350 (2010).
63. Broyl A, Kuiper R, van Duin M et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121(4), 624-627 (2013).
64. Lopez-Girona A, Mendy D, Ito T et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11), 2326-2335 (2012).
65. Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118(18), 4771-4779(2011).
66. Dimopoulos MA, Lacy MQ, Moreau P et al. Pomalidomide in combination with low-dose dexamethasone demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A Phase 3, multicenter, randomized, open-label study. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012.
67. Lacy MQ, LaPlant BR, Laumann K et al. Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: Long term follow up and factors predicting outcome in 345 patients. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012.
68. Kropff M, Baylon HG, Hillengass J et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: Results from OPTIMUM, a randomized trial. Haematologica 97(5), 784-791 (2012).
69. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 23(3), 449-456 (2009).
70. Scaglione F, Ferrara F, Dugnani S, Demartini G, Triscari F, Fraschini F. Immunostimulation by clarithromycin in healthy volunteers and chronic bronchitis patients. J. Chemother. 5(4), 228-232 (1993).
71. Matsuoka N, Eguchi K, Kawakami A et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin. Exp. Immunol. 104(3), 501-508 (1996).
72. Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: A potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 210(3), 781-786 (1995).
73. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res. 24(6), 3723-3730 (2004).
74. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H. Clarithromycin attenuates autophagy in myeloma cells. Int. J. Oncol. 37(4), 815-820 (2010).
75. Mark TM, Boyer A, Rossi AC et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012.
76. Palumbo A, Larocca A, Montefusco V et al. Pomalidomide cyclophosphamide and Prednisone (PCP) treatment for relapsed/refractory multiple myeloma. Presented: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012.
77. Richardson PG, Hofmeister CC, Siegel D et al. MM-005 a Phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012.